{"organizations": [], "uuid": "185d0f51b779af3d4791d756d30d5b673ee20947", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/03/08/the-associated-press-oncomed-tops-street-4q-forecasts.html", "country": "US", "domain_rank": 767, "title": "OncoMed tops Street 4Q forecasts", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-08T23:37:00.000+02:00", "replies_count": 0, "uuid": "185d0f51b779af3d4791d756d30d5b673ee20947"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/03/08/the-associated-press-oncomed-tops-street-4q-forecasts.html", "ord_in_thread": 0, "title": "OncoMed tops Street 4Q forecasts", "locations": [], "entities": {"persons": [], "locations": [{"name": "redwood city", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "redwood city", "sentiment": "none"}], "organizations": [{"name": "oncomed pharmaceuticals inc.", "sentiment": "negative"}, {"name": "omed", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "REDWOOD CITY, Calif. (AP) _ OncoMed Pharmaceuticals Inc. (OMED) on Thursday reported fourth-quarter net income of $9.5 million, after reporting a loss in the same period a year earlier.\nThe Redwood City, California-based company said it had profit of 25 cents per share.\nThe results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 31 cents per share.\nThe cancer therapy developer posted revenue of $20.6 million in the period, which also topped Street forecasts. Four analysts surveyed by Zacks expected $5.1 million.\nFor the year, the company reported that its loss narrowed to $39.1 million, or $1.04 per share. Revenue was reported as $38.2 million.\nIn the final minutes of trading on Thursday, the company's shares hit $2.89. A year ago, they were trading at $9.14.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on OMED at https://www.zacks.com/ap/OMED", "external_links": [], "published": "2018-03-08T23:37:00.000+02:00", "crawled": "2018-03-09T09:50:57.000+02:00", "highlightTitle": ""}